Seattle Cannabis Blockbuster Set to Double Sales in Next 2 Years!
Thanks to a recent reorganization, acquisitions and strategic partnerships, one Seattle cannabis blockbuster is poised for a massive expansion in the coming 24 months. With plans to double its annual sales in the next two years, this company's shares could potentially skyrocket in value.
Get all the details on this potential penny stock

DBTX Insider Trading (Decibel Therapeutics)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $13,126,400.00
Insider Selling (Last 12 Months): $40,498.20

Decibel Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Decibel Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Decibel Therapeutics Share Price & Price History

Current Price: $7.47
Price Change: Price Increase of +0.2 (2.75%)
As of 10/20/2021 01:00 AM ET

This chart shows the closing price history over time for DBTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Small Cap Wonder
Read why this microcap stock might stand out in the market.
Get the info now.

Decibel Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/14/2021Anna TraskInsiderSell5,364$7.55$40,498.20View SEC Filing Icon  
9/15/2021Laurence ReidInsiderBuy10,000$7.64$76,400.0025,849View SEC Filing Icon  
2/17/2021Casdin Partners Master Fund, LMajor ShareholderBuy575,000$18.00$10,350,000.00View SEC Filing Icon  
2/17/2021Plc GlaxosmithklineDirectorBuy150,000$18.00$2,700,000.00View SEC Filing Icon  
See Full Table
Insider Buying at Decibel Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Decibel Therapeutics and related companies.

SEC Filings (Institutional Ownership Changes) for Decibel Therapeutics (NASDAQ:DBTX)

71.92% of Decibel Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at DBTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Decibel Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/23/2021Morgan Stanley75,387$0.65M0.0%+918.3%0.303%Search for SEC Filing on Google Icon
8/17/2021Millennium Management LLC69,917$0.60M0.0%-51.3%0.281%Search for SEC Filing on Google Icon
8/17/2021Bridgeway Capital Management LLC72,000$0.62M0.0%N/A0.289%Search for SEC Filing on Google Icon
8/17/2021Citadel Advisors LLC1,773,831$14.94M0.0%-0.3%7.123%Search for SEC Filing on Google Icon
8/16/2021Alberta Investment Management Corp30,000$0.26M0.0%N/A0.120%Search for SEC Filing on Google Icon
8/16/2021Alyeska Investment Group L.P.27,047$0.23M0.0%-42.1%0.109%Search for SEC Filing on Google Icon
8/16/2021Morgan Stanley75,387$0.65M0.0%+918.3%0.303%Search for SEC Filing on Google Icon
8/16/2021Credit Suisse AG253,851$2.18M0.0%N/A1.019%Search for SEC Filing on Google Icon
8/16/2021Tibra Equities Europe Ltd43,400$0.37M0.1%N/A0.174%Search for SEC Filing on Google Icon
8/16/2021Federated Hermes Inc.10,000$86K0.0%-50.0%0.040%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC15,900$0.14M0.0%N/A0.064%Search for SEC Filing on Google Icon
8/13/2021Northern Trust Corp15,239$0.13M0.0%-80.3%0.061%Search for SEC Filing on Google Icon
8/13/2021Laurion Capital Management LP20,305$0.18M0.0%-18.8%0.082%Search for SEC Filing on Google Icon
8/13/2021Neuberger Berman Group LLC43,350$0.37M0.0%+54.8%0.174%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC71,848$0.62M0.0%-34.7%0.289%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.371,774$3.20M0.0%+102.9%1.493%Search for SEC Filing on Google Icon
8/13/2021FMR LLC213,800$1.84M0.0%-50.6%0.859%Search for SEC Filing on Google Icon
8/12/2021JPMorgan Chase & Co.216,722$1.86M0.0%-11.1%0.870%Search for SEC Filing on Google Icon
8/11/2021Bank of New York Mellon Corp27,310$0.24M0.0%+124.0%0.110%Search for SEC Filing on Google Icon
8/11/2021BlackRock Inc.1,824,310$15.69M0.0%-15.4%7.326%Search for SEC Filing on Google Icon
8/9/2021O Shaughnessy Asset Management LLC12,821$0.11M0.0%N/A0.051%Search for SEC Filing on Google Icon
8/9/2021Bronte Capital Management Pty Ltd.159,462$1.37M0.1%N/A0.640%Search for SEC Filing on Google Icon
7/31/2021Atlas Capital Advisors LLC17,798$0.15M0.0%N/A0.071%Search for SEC Filing on Google Icon
5/18/2021Millennium Management LLC143,470$1.63M0.0%N/A0.576%Search for SEC Filing on Google Icon
5/18/2021Zimmer Partners LP50,000$0.57M0.0%N/A0.201%Search for SEC Filing on Google Icon
5/18/2021Morgan Stanley7,403$84K0.0%N/A0.030%Search for SEC Filing on Google Icon
5/18/2021Orbimed Advisors LLC4,945,192$56.18M0.5%N/A19.859%Search for SEC Filing on Google Icon
5/18/2021Alyeska Investment Group L.P.46,700$0.53M0.0%N/A0.188%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC1,778,396$20.20M0.0%N/A7.142%Search for SEC Filing on Google Icon
5/18/2021California State Teachers Retirement System10,754$0.12M0.0%N/A0.043%Search for SEC Filing on Google Icon
5/18/2021Samsara BioCapital LLC826,422$9.39M1.7%N/A3.319%Search for SEC Filing on Google Icon
5/17/2021Suvretta Capital Management LLC263,600$2.99M0.0%N/A1.059%Search for SEC Filing on Google Icon
5/17/2021Woodline Partners LP280,511$3.19M0.1%N/A1.126%Search for SEC Filing on Google Icon
5/17/2021Caas Capital Management LP10,000$0.11M0.0%N/A0.040%Search for SEC Filing on Google Icon
5/17/2021Janus Henderson Group PLC693,986$7.54M0.0%N/A2.787%Search for SEC Filing on Google Icon
5/17/2021Nuveen Asset Management LLC11,549$0.13M0.0%N/A0.046%Search for SEC Filing on Google Icon
5/14/2021Laurion Capital Management LP25,000$0.28M0.0%N/A0.100%Search for SEC Filing on Google Icon
5/14/2021Monashee Investment Management LLC57,401$0.65M0.1%N/A0.231%Search for SEC Filing on Google Icon
5/13/2021Bessemer Group Inc.494,071$5.61M0.0%N/A1.984%Search for SEC Filing on Google Icon
5/13/2021Neuberger Berman Group LLC28,000$0.32M0.0%N/A0.112%Search for SEC Filing on Google Icon
5/13/2021Bank of New York Mellon Corp12,193$0.14M0.0%N/A0.049%Search for SEC Filing on Google Icon
5/13/2021Federated Hermes Inc.20,000$0.23M0.0%N/A0.080%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp77,392$0.88M0.0%N/A0.311%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC109,944$1.25M0.0%N/A0.442%Search for SEC Filing on Google Icon
5/12/2021TRV GP Iii LLC3,139,685$35.67M4.5%N/A12.608%Search for SEC Filing on Google Icon
5/12/2021JPMorgan Chase & Co.243,828$2.77M0.0%N/A0.979%Search for SEC Filing on Google Icon
5/12/2021UBS Group AG3,015$34K0.0%N/A0.012%Search for SEC Filing on Google Icon
5/11/2021New York State Common Retirement Fund6,800$77K0.0%N/A0.027%Search for SEC Filing on Google Icon
5/7/2021BlackRock Inc.2,156,804$24.50M0.0%N/A8.661%Search for SEC Filing on Google Icon
5/7/2021American International Group Inc.4,155$47K0.0%N/A0.017%Search for SEC Filing on Google Icon
5/7/2021Harvard Management Co. Inc.328,798$3.74M0.2%N/A1.320%Search for SEC Filing on Google Icon
5/4/2021Victory Capital Management Inc.51,139$0.58M0.0%N/A0.205%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.
Read More on Decibel Therapeutics

Today's Range

Now: $7.47
Low: $7.19
High: $7.47

50 Day Range

MA: $7.81
Low: $7.00
High: $8.74

52 Week Range

Now: $7.47
Low: $6.18
High: $24.39

Volume

35,626 shs

Average Volume

104,260 shs

Market Capitalization

$185.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Decibel Therapeutics?

Decibel Therapeutics' top insider shareholders include:
  1. Laurence Reid (Insider)
  2. Anna Trask (Insider)
  3. Casdin Partners Master Fund, L (Major Shareholder)
  4. Plc Glaxosmithkline (Director)
Seattle Cannabis Blockbuster Set to Double Sales in Next 2 Years!
Thanks to a recent reorganization, acquisitions and strategic partnerships, one Seattle cannabis blockbuster is poised for a massive expansion in the coming 24 months. With plans to double its annual sales in the next two years, this company's shares could potentially skyrocket in value.
Get all the details on this potential penny stock